Cytek Biosciences (CTKB) EBIT Margin (2020 - 2026)

Cytek Biosciences has reported EBIT Margin for 7 years, with the latest figure at 41.83% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin fell 571.0% year-over-year to 41.83%; the trailing twelve-month figure through Mar 2026 stood at 21.49% (down 892.0% YoY), and the FY2025 full-year result was 20.04%, down 980.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 41.83%, down from 9.0% in the prior quarter.
• The five-year high for EBIT Margin was 5.2% in Q4 2024, with the low at 41.83% in Q1 2026.
• Historically, EBIT Margin has averaged 14.31% across 5 years, with a median of 13.38% in 2023.
• Annual changes were most pronounced in 2023 — EBIT Margin slumped 2607 bps — and 2024, when it jumped 886 bps.
• Cytek Biosciences' EBIT Margin stood at 0.17% in 2022, then tumbled by 235 bps to 0.24% in 2023, then surged by 2308 bps to 5.2% in 2024, then slumped by 273 bps to 9.0% in 2025, then slumped by 365 bps to 41.83% in 2026.
• The last three EBIT Margin figures came in at 41.83% (Q1 2026), 9.0% (Q4 2025), and 17.58% (Q3 2025), per Business Quant data.